1
|
Liu M, Du X, Chen H, Bai C, Lan L. Systemic investigation of di-isobutyl phthalate (DIBP) exposure in the risk of cardiovascular via influencing the gut microbiota arachidonic acid metabolism in obese mice model. Regen Ther 2024; 27:290-300. [PMID: 38638558 PMCID: PMC11024931 DOI: 10.1016/j.reth.2024.03.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 03/17/2024] [Accepted: 03/24/2024] [Indexed: 04/20/2024] Open
Abstract
Phthalate esters (PE), a significant class of organic compounds used in industry, can contaminate humans and animals by entering water and food chains. Recent studies demonstrate the influence of PE on the development and progression of heart diseases, particularly in obese people. Di-isobutyl phthalate (DIBP) was administered orally to normal and diet-induced obese mice in this research to assess cardiovascular risk. The modifications in the microbial composition and metabolites were examined using RNA sequencing and mass spectrometry analysis. Based on the findings, lean group rodents were less susceptible to DIBP exposure than fat mice because of their cardiovascular systems. Histopathology examinations of mice fed a high-fat diet revealed lesions and plagues that suggested a cardiovascular risk. In the chronic DIBP microbial remodeling metagenomics Faecalibaculum rodentium was the predominant genera in obese mice. According to metabolomics data, arachidonic acid (AA) metabolism changes caused by DIBP were linked to unfavorable cardiovascular events. Our research offers new understandings of the cardiovascular damage caused by DIBP exposure in obese people and raises the possibility that arachidonic acid metabolism could be used as a regulator of the gut microbiota to avert related diseases.
Collapse
Affiliation(s)
- Min Liu
- Department of General Practice, First Hospital of Shanxi Medical University, No.85, Jiefang South Road, Taiyuan, Shanxi, 030001, China
| | - Xifeng Du
- Department of General Practice, First Hospital of Shanxi Medical University, No.85, Jiefang South Road, Taiyuan, Shanxi, 030001, China
| | - Huifang Chen
- Department of General Practice, First Hospital of Shanxi Medical University, No.85, Jiefang South Road, Taiyuan, Shanxi, 030001, China
| | - Chenkai Bai
- Department of General Practice, First Hospital of Shanxi Medical University, No.85, Jiefang South Road, Taiyuan, Shanxi, 030001, China
| | - Lizhen Lan
- Department of General Practice, First Hospital of Shanxi Medical University, No.85, Jiefang South Road, Taiyuan, Shanxi, 030001, China
| |
Collapse
|
2
|
Trasande L, Krithivasan R, Park K, Obsekov V, Belliveau M. Chemicals Used in Plastic Materials: An Estimate of the Attributable Disease Burden and Costs in the United States. J Endocr Soc 2024; 8:bvad163. [PMID: 38213907 PMCID: PMC10783259 DOI: 10.1210/jendso/bvad163] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Indexed: 01/13/2024] Open
Abstract
Context Chemicals used in plastics have been described to contribute to disease and disability, but attributable fractions have not been quantified to assess specific contributions. Without this information, interventions proposed as part of the Global Plastics Treaty cannot be evaluated for potential benefits. Objective To accurately inform the tradeoffs involved in the ongoing reliance on plastic production as a source of economic productivity in the United States, we calculated the attributable disease burden and cost due to chemicals used in plastic materials in 2018. Methods We first analyzed the existing literature to identify plastic-related fractions (PRF) of disease and disability for specific polybrominated diphenylethers (PBDE), phthalates, bisphenols, and polyfluoroalkyl substances and perfluoroalkyl substances (PFAS). We then updated previously published disease burden and cost estimates for these chemicals in the United States to 2018. By uniting these data, we computed estimates of attributable disease burden and costs due to plastics in the United States. Results We identified PRFs of 97.5% for bisphenol A (96.25-98.75% for sensitivity analysis), 98% (96%-99%) for di-2-ethylhexylphthalate, 100% (71%-100%) for butyl phthalates and benzyl phthalates, 98% (97%-99%) for PBDE-47, and 93% (16%-96%) for PFAS. In total, we estimate $249 billion (sensitivity analysis: $226 billion-$289 billion) in plastic-attributable disease burden in 2018. The majority of these costs arose as a result of PBDE exposure, though $66.7 billion ($64.7 billion-67.3 billion) was due to phthalate exposure and $22.4 billion was due to PFAS exposure (sensitivity analysis: $3.85-$60.1 billion). Conclusion Plastics contribute substantially to disease and associated social costs in the United States, accounting for 1.22% of the gross domestic product. The costs of plastic pollution will continue to accumulate as long as exposures continue at current levels. Actions through the Global Plastics Treaty and other policy initiatives will reduce these costs in proportion to the actual reductions in chemical exposures achieved.
Collapse
Affiliation(s)
- Leonardo Trasande
- Department of Pediatrics, NYU Grossman School of Medicine, NewYork, NY 10016, USA
- Department of Population Health, NYU Grossman School of Medicine, NewYork, NY 10016, USA
- NYU Wagner Graduate School of Public Service, NewYork, NY 10012, USA
| | | | - Kevin Park
- Department of Medicine, NYU Grossman School of Medicine, NewYork, NY 10016, USA
| | | | | |
Collapse
|
3
|
Martínez-Pinna J, Sempere-Navarro R, Medina-Gali RM, Fuentes E, Quesada I, Sargis RM, Trasande L, Nadal A. Endocrine disruptors in plastics alter β-cell physiology and increase the risk of diabetes mellitus. Am J Physiol Endocrinol Metab 2023; 324:E488-E505. [PMID: 37134142 PMCID: PMC10228669 DOI: 10.1152/ajpendo.00068.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 04/27/2023] [Accepted: 04/28/2023] [Indexed: 05/05/2023]
Abstract
Plastic pollution breaks a planetary boundary threatening wildlife and humans through its physical and chemical effects. Of the latter, the release of endocrine disrupting chemicals (EDCs) has consequences on the prevalence of human diseases related to the endocrine system. Bisphenols (BPs) and phthalates are two groups of EDCs commonly found in plastics that migrate into the environment and make low-dose human exposure ubiquitous. Here we review epidemiological, animal, and cellular studies linking exposure to BPs and phthalates to altered glucose regulation, with emphasis on the role of pancreatic β-cells. Epidemiological studies indicate that exposure to BPs and phthalates is associated with diabetes mellitus. Studies in animal models indicate that treatment with doses within the range of human exposure decreases insulin sensitivity and glucose tolerance, induces dyslipidemia, and modifies functional β-cell mass and serum levels of insulin, leptin, and adiponectin. These studies reveal that disruption of β-cell physiology by EDCs plays a key role in impairing glucose homeostasis by altering the mechanisms used by β-cells to adapt to metabolic stress such as chronic nutrient excess. Studies at the cellular level demonstrate that BPs and phthalates modify the same biochemical pathways involved in adaptation to chronic excess fuel. These include changes in insulin biosynthesis and secretion, electrical activity, expression of key genes, and mitochondrial function. The data summarized here indicate that BPs and phthalates are important risk factors for diabetes mellitus and support a global effort to decrease plastic pollution and human exposure to EDCs.
Collapse
Affiliation(s)
- Juan Martínez-Pinna
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain
- Departamento de Fisiología, Genética y Microbiología, Universidad de Alicante, Alicante, Spain
| | - Roberto Sempere-Navarro
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Regla M Medina-Gali
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Esther Fuentes
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Ivan Quesada
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Robert M Sargis
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States
| | - Leonardo Trasande
- Department of Pediatrics, New York University Grossman School of Medicine, New York, New York, United States
- Department of Population Health, New York University Grossman School of Medicine, New York, New York, United States
- Wagner School of Public Service, New York University, New York, New York, United States
| | - Angel Nadal
- Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, Elche, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
4
|
Bidashimwa D, Hoke T, Huynh TB, Narkpitaks N, Priyonugroho K, Ha TT, Burns A, Weissman A. Plastic pollution: how can the global health community fight the growing problem? BMJ Glob Health 2023; 8:e012140. [PMID: 37295791 PMCID: PMC10277055 DOI: 10.1136/bmjgh-2023-012140] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 05/06/2023] [Indexed: 06/12/2023] Open
Affiliation(s)
| | - Theresa Hoke
- Health Service Research, FHI 360, Durham, North Carolina, USA
| | - Thu Ba Huynh
- Asia Pacific Regional Office, FHI 360, Bangkok, Thailand
| | | | | | - Trinh Thai Ha
- Asia Pacific Regional Office, FHI 360, Hanoi, Vietnam
| | - Allison Burns
- Knowledge Exchange, FHI 360, Durham, North Carolina, USA
| | - Amy Weissman
- Asia Pacific Regional Office, FHI 360, Bangkok, Thailand
| |
Collapse
|
5
|
Plastic pollution requires an integrative systems approach to understand and mitigate risk. Emerg Top Life Sci 2022; 6:435-439. [PMID: 36453918 DOI: 10.1042/etls20220018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 11/07/2022] [Accepted: 11/09/2022] [Indexed: 12/02/2022]
Abstract
To date, much effort has been placed on quantifying plastic pollution and understanding its negative environmental effects, arguably to the detriment of research and evaluation of potential interventions. This has led to piecemeal progress in interventions to reduce plastic pollution, which do not correspond to the pace of emissions. For substances that are used on a global scale and identified as hazardous, there is a need to act before irreversible damage is done. For example, the history of dichlorodiphenyltrichloethane's (DDT) use has demonstrated that legacy chemicals with properties of persistence can still be found in the environment despite being first prohibited 50 years ago. Despite the growing evidence of harm, evidence to inform actions to abate plastic pollution lag behind. In part, this is because of the multifaceted nature of plastic pollution and understanding the connections between social, economic and environmental dimensions are complex. As such we highlight the utility of integrative systems approaches for addressing such complex issues, which unites a diversity of stakeholders (including policy, industry, academia and society), and provides a framework to identify to develop specific, measurable and time-bound international policies on plastic pollution and meet the ambitious yet necessary goals of the UN Plastic Treaty.
Collapse
|
6
|
Deeney M, Yates J, Green R, Kadiyala S. Centring human health in the global plastics treaty: a call to action. BMJ Glob Health 2022; 7:e011040. [PMID: 36375851 PMCID: PMC9664311 DOI: 10.1136/bmjgh-2022-011040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 10/22/2022] [Indexed: 11/16/2022] Open
Affiliation(s)
- Megan Deeney
- Department of Population Health, London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, London, UK
| | - Joe Yates
- Department of Population Health, London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, London, UK
| | - Rosemary Green
- Department of Population Health, London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, London, UK
| | - Suneetha Kadiyala
- Department of Population Health, London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, London, UK
| |
Collapse
|